to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers

An Open-label Phase I Clinical Trial to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers

This is a phase 1 study to evaluate the safety of Ga68-Dolacga Injection in healthy volunteers and to assess the normal reference range and inter-individual variability of the Ga68-Dolacga Injection in estimating liver reserve in healthy volunteers.

Ga-68 is a positron-emitting radionuclide with short half-life of 68 minutes. Dolacga is a non-radiolabeled formulated drug product and will be reconstituted to become the finished radiopharmaceutical product Ga68-Dolacga Injection, a PET tracer specifically targeting to surface receptors of hepatocytes. The study aims to evaluate the safety of Ga68-Dolacga Injection in healthy volunteers and to assess the normal reference range and inter-individual variability of the Ga68-Dolacga Injection in estimating liver reserve in healthy volunteers.

Inclusion Criteria:

1. Written informed consent must be obtained before any assessment is performed.
2. Male or female subjects aged 20 or above, inclusive, at date of consent.
3. Body mass index (BMI) between 18.5 and 23.0, inclusive, (BMI will be calculated as weight in kilogram [kg]/height in meters2 [m2])
4. Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of child-bearing potential, must commit to use a barrier contraception method for the duration of the study.
5. Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method for male subjects for the study duration.
6. Male subjects must not donate sperm for the study duration.
7. Willing and able to cooperate with study procedures
8. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, and ECG
9. Laboratory values within reference range, unless values are deemed by the Principal Investigator as "Not Clinically Significant"
10. Negative result for hepatitis B and C antigen test

Exclusion Criteria:

1. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product as stated in this protocol
2. Implantation of metal devices including cardiac pacemaker, intravascular metal devices
3. Current or prior history of major psychiatric disorders, epilepsy and major depression
4. History of positive test for human immunodeficiency virus (HIV)
5. History of chronic alcohol or drug abuse within the last 6 months
6. Pregnant women, lactating or breast-feeding women
7. Clinically significant abnormal laboratory values and/or clinically significant or unstable medical illness
8. General PET exclusion criteria
9. Prior participation in nuclear medicine treatments or computer tomography examinations in the last year
10. Subject has received an investigational drug or device within 30 days of screening.
11. Subjects having high risks for the study according to the PI discretion
12. Subjects who can't be followed up for any reason